Alecensa (alectinib) / Roche 
Welcome,         Profile    Billing    Logout  
 13 Diseases   52 Trials   52 Trials   3235 News 


«12...7891011121314151617...3637»
  • ||||||||||  Alecensa (alectinib) / Roche
    Journal:  Development of Alectinib-Suspended SNEDDS for Enhanced Solubility and Dissolution. (Pubmed Central) -  Aug 27, 2022   
    In the dispersion test and microscopic observation, micronized ALH particles in the Su-SNEDDS were readily dispersed in the dissolution medium with spontaneous nanoemulsion formation and instantly solubilized with the aid of SLS. Taken together, our results suggest that the Su-SNEDDS would be a potent oral dosage form to enhance the solubilization and dissolution rate of ALH in a new technological way.
  • ||||||||||  Lorbrena (lorlatinib) / Pfizer, Alunbrig (brigatinib) / Takeda, Alecensa (alectinib) / Roche
    Preclinical, Journal:  Novel human-derived EML4-ALK fusion cell lines identify ribonucleotide reductase RRM2 as a target of activated ALK in NSCLC. (Pubmed Central) -  Aug 22, 2022   
    We provide a characterization of four novel EML4-ALK-positive NSCLC cell lines, highlighting genomic heterogeneity and differential responses to ALK TKI treatment. The RNA-Seq characterization of ALK-positive NSCLC CUTO8, CUTO9, CUTO29 and YU1077 cell lines reported here, has been compiled in an interactive ShinyApp resource for public data exploration (https://ccgg.ugent.be/shiny/nsclc_rrm2_2022/).
  • ||||||||||  Xalkori (crizotinib) / Pfizer, Alecensa (alectinib) / Roche
    Journal:  Multiple pulmonary nodules with interstitial changes (Pubmed Central) -  Aug 13, 2022   
    The patient received therapies with crizotinib, alectinib in sequence and anticoagulation. After 20-month treatment, a telephone follow-up showed that there was no significant limitation in her daily activities.
  • ||||||||||  7-Hydroxystaurosporine (UCN-01) / National Cancer Institute, Alecensa (alectinib) / Roche
    Journal, IO biomarker, Pan tumor:  Comprehensive Bioinformatics Analysis of Toll-Like Receptors (TLRs) in Pan-Cancer. (Pubmed Central) -  Aug 10, 2022   
    TLR7 was significantly positively correlated with the drug sensitivity of alectinib. Our study reveals the significant role of TLRs family in pan-cancer and provides potential therapeutic strategies of cancer.
  • ||||||||||  Alecensa (alectinib) / Roche
    CNS Outcomes in ALK Fusion Positive NSCLC Patients with BM Who Received Alectinib with or without Local Therapy (Henry B. Gonzalez Convention Center, Exhibit Hall 1) -  Aug 1, 2022 - Abstract #ASTRO2022ASTRO_624;    
    Despite the fact that patients with ALK fusion positive NSCLC treated with alectinib + LT had larger BM and a greater likelihood of pre-treatment neurologic symptoms, the iPFS was similar between the patients treated with alectinib only and alectinib + LT. With newer generation TKIs which may have CNS penetrance, further prospective studies are required to identify which patients are most likely to benefit from the addition of LT to ALK-directed therapy.
  • ||||||||||  Xalkori (crizotinib) / Pfizer, Zykadia (ceritinib) / Novartis, Alecensa (alectinib) / Roche
    Review, Journal:  Anaplastic lymphoma kinase inhibitors and their effect on the kidney. (Pubmed Central) -  Jul 29, 2022   
    According to the package insert and published literature, treatment with several ALK-1 inhibitors appears to be associated with the development of peripheral edema and rare electrolyte disorders, kidney failure, proteinuria and an increased risk for the development and progression of renal cysts. This review introduces the different types of ALK inhibitors, focusing on their detailed kidney-related side effects in clinical practice.
  • ||||||||||  Alecensa (alectinib) / Roche
    MET and NF2 alterations confer early resistance to first-line alectinib treatment in ALK-rearranged non-small cell lung cancer (Poster Area, Hall 4) -  Jul 28, 2022 - Abstract #ESMO2022ESMO_2897;    
    Also, NF2-mutant patients only had a median PFS of 4 months, significantly poorer than those without (HR 11.1, 95CI 2.17-50; p<0.001). Conclusions By analyzing different mutational profiles of ALK-rearranged patients after alectinib treatment, we proposed MET and NF2 as putative mechanisms that conferred resistance to early resistance of first-line alectinib, which shone light on future tailored treatment for ALK-positive NSCLCs.
  • ||||||||||  Alunbrig (brigatinib) / Takeda, Alecensa (alectinib) / Roche
    Integrated biomarker analysis of brigatinib efficacy in anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) refractory to alectinib (Poster Area, Hall 4) -  Jul 28, 2022 - Abstract #ESMO2022ESMO_1931;    
    P2
    The presence of secondary ALK mutations at baseline was associated with a similar ORR (34.5%) and median DoR (5.6 months) and shorter median PFS (3.7 months), with response/clinical benefit observed in pts with G1202R, L1196M, and I1171N ALK secondary mutations. Table: 1009P Brigatinib efficacy parameters a according to baseline ALK mutation status a Blinded independent review committee–-assessed CI, confidence interval Conclusions Brigatinib showed clinically meaningful activity in pts with alectinib-resistant ALK+ NSCLC with or without a detectable ALK fusion and/or secondary mutations.
  • ||||||||||  Alecensa (alectinib) / Roche
    Journal:  ALK-fusion-positive secondary ameloblastic carcinoma reached complete response after using alectinib. (Pubmed Central) -  Jul 28, 2022   
    Table: 1009P Brigatinib efficacy parameters a according to baseline ALK mutation status a Blinded independent review committee–-assessed CI, confidence interval Conclusions Brigatinib showed clinically meaningful activity in pts with alectinib-resistant ALK+ NSCLC with or without a detectable ALK fusion and/or secondary mutations. No abstract available
  • ||||||||||  Alecensa (alectinib) / Roche
    Journal:  Symptomatic Bradycardia Due to Alectinib in a Patient with Advanced Stage of NSCLC. (Pubmed Central) -  Jul 15, 2022   
    Meanwhile, bradycardia was reported as a very common adverse effect, but generally asymptomatic, unlike the reported patient in this case report. This case report's purpose is to increase awareness of the possibility of adverse effects due to alectinib administration that require immediate intervention in order to improve the quality of life and patient survival, especially in patients with advanced NSCLC.
  • ||||||||||  Trial completion date, Trial initiation date, Trial primary completion date:  SMMART Adaptive Clinical Treatment (ACT) Trial (clinicaltrials.gov) -  Jul 14, 2022   
    P2,  N=131, Not yet recruiting, 
    After 34 follow-up months, the patient remained in oncological remission and the child's physical development is normal. Trial completion date: Mar 2025 --> Mar 2026 | Initiation date: Apr 2022 --> Dec 2022 | Trial primary completion date: Mar 2025 --> Mar 2026
  • ||||||||||  Xalkori (crizotinib) / Pfizer, Alecensa (alectinib) / Roche
    Biomarker, Journal:  Case report: molecular analysis of congenital glioblastoma in a newborn (Pubmed Central) -  Jun 28, 2022   
    We found polysomy of chromosome 2 and 5' deletion of the ALK gene in the glioma cells by ALK FISH. This result indicates the importance of molecular analyses in the diagnostic evaluation of cGBM, and raises the possibility of a personalized, targeted therapy (crizotinib, alectinib).
  • ||||||||||  Alecensa (alectinib) / Roche
    Journal:  Targeting ALK in Neuroendocrine Tumors of the Lung. (Pubmed Central) -  Jun 28, 2022   
    Two out of three patients with metastatic ALK-rearranged LCNEC received up-front treatment with the ALK TKI alectinib and showed rapid tumor response at all metastatic sites, including multiple brain metastases...Contrarily to NSCLC, the detection of ALK rearrangements in neuroendocrine tumors of the lung is challenging, since ALK IHC can lead to false-positive results and therefore needs confirmation by FISH or NGS. Up-front comprehensive molecular profiling with NGS should be performed in metastatic LCNEC in order not to miss actionable genomic alterations.
  • ||||||||||  Alecensa (alectinib) / Roche
    Phase II NAUTIKA1 Study of Targeted Therapies in Stage II-III NSCLC: Preliminary Data of Neoadjuvant Alectinib for ALK+ NSCLC (Exhibit Hall - Hall B) -  Jun 24, 2022 - Abstract #IASLCWCLC2022IASLC_WCLC_1775;    
    P2
    Despite some technical intra-operative difficulties, salvage surgery was safe and feasible after alectinib for (locally) advanced NSCLC and an impressive pathological response may be often obtained in the surgical specimens. In this preliminary analysis from the ALK+ cohort of NAUTIKA1, alectinib was well tolerated in patients with ALK+ NSCLC and is considered feasible for neoadjuvant treatment.
  • ||||||||||  Tecentriq (atezolizumab) / Roche, Alecensa (alectinib) / Roche
    SCLC Transformation from ALK-rearranged Lung Adenocarcinoma after Alectinib Resistance and Response to Atezolizumab: Case Report (Exhibit Hall - Hall B) -  Jun 24, 2022 - Abstract #IASLCWCLC2022IASLC_WCLC_1329;    
    Introduction: The genotypic and histological evolution of non-small cell lung cancer (NSCLC) to small cell lung cancer (SCLC) has been described as a mechanism of acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy. The cases highlighted the importance of re-biopsy that identified pathologically SCLC transformation after ALK-TKI resistance, and suggested the treatment of atezolizumab plus carboplatin, and etoposide, which could provide a reference for such phenotype.